Omega Healthcare Investors, Inc.

Omega Healthcare Investors, Inc. Earnings Recaps

OHI Real Estate 3 recaps
Next earnings: February 3, 2027 (estimated) · full calendar
Q3 2026 Nov 9, 2026

Omega’s shares rose 3.5% after earnings, with investors likely responding to the highly accretive PACS transition and the company’s deployment of more than $1 billion in the second half to date. Sequential AFFO and FAD were effectively flat, tempering the positive operating and transaction updates.

Key takeaways
  • Third-quarter AFFO was $0.82 per share and FAD was $0.78; both were effectively flat sequentially, partly due to $563 million of asset sales late in the second quarter.
  • The 32-facility transition to PACS raises first-year annual rent by $26.1 million, is expected to add about $0.065 per share in annualized FAD, and includes a $90 million termination fee paid to the prior operator.
  • Omega completed $181 million of third-quarter investments: $167 million in real estate acquisitions and $14 million in loan fundings. It said it had allocated more than $1 billion in the second half of the year to date.
  • Trailing 12-month operator EBITDAR coverage improved to 1.67x from 1.65x; occupancy edged up to 82.7% from 82.6%.
  • The Genesis bankruptcy sale was finalized in October: Omega’s master lease was assumed and assigned to a NewGen affiliate, and Omega received repayment of its DIP loan and a $150 million term loan.
Q2 2026 Aug 1, 2026

Shares declined 1.4% following Q2 results as investors reacted cautiously to flat sequential AFFO and ongoing asset sales weighing on near-term earnings, despite management’s optimism on longer-term earnings accretion from capital redeployment.

Key takeaways
  • Q2 AFFO was $0.83 per share, showing year-over-year growth but effectively flat sequentially due to a $563 million asset sale headwind.
  • Asset sales occurred at an effective 6.7% cap rate on cash flow, intended to strengthen credit support for operators and fund future accretive acquisitions.
  • Management signaled transaction volumes for the remainder of 2026 and into 2027 are expected to increase meaningfully.
  • Recent acquisitions, including the first U.K. care home operating company, are structured to deliver higher earnings accretion compared to traditional triple net deals.
  • While the underlying strategy targets long-term value, the flat near-term earnings and sales-related headwinds may have tempered investor enthusiasm.
Q1 2026 Apr 30, 2026

Omega Healthcare Investors shares drifted 0.9% lower post-earnings as results and outlook were largely in line with expectations. Though management highlighted a rising AFFO guidance midpoint and strong FAD growth, no upside surprise or disappointment was evident.

Key takeaways
  • First quarter AFFO of $0.82 per share and FAD of $0.78 per share, with the FAD per share up 9.5% year-over-year.
  • Management raised the low end of FY26 AFFO guidance, moving the midpoint up by $0.02 to $3.22.
  • Dividend payout ratios for the quarter were 82% (AFFO) and 86% (FAD), reflecting improved coverage.
  • Executed or announced $326 million in new investments year-to-date and completed or pending $480 million of asset sales, primarily the sale of 18 Communicare facilities.
  • Portfolio performance remains strong, with core EBITDAR coverage at 1.58x, the highest in over a decade; Genesis restructuring and DIP loan exposure remain in focus.